DOI QR코드

DOI QR Code

Current Trends and Recent Advances in Diagnosis, Therapy, and Prevention of Hepatocellular Carcinoma

  • Wang, Chun-Hsiang (Department of Hepatogastroenterology, Tainan Municipal Hospital) ;
  • Wey, Keh-Cherng (Department of Hepatogastroenterology, Tainan Municipal Hospital) ;
  • Mo, Lein-Ray (Department of Hepatogastroenterology, Tainan Municipal Hospital) ;
  • Chang, Kuo-Kwan (Department of Hepatogastroenterology, Tainan Municipal Hospital) ;
  • Lin, Ruey-Chang (Department of Hepatogastroenterology, Tainan Municipal Hospital) ;
  • Kuo, Jen-Juan (Department of Hepatogastroenterology, Tainan Municipal Hospital)
  • Published : 2015.05.18

Abstract

Hepatocellular carcinoma (HCC) has been one of the most fatal malignant tumors worldwide and its associated morbidity and mortality remain of significant concern. Based on in-depth reviews of serological diagnosis of HCC, in addition to AFP, there are other biomarkers: Lens culinaris agglutinin-reactive AFP (AFP-L3), descarboxyprothrombin (DCP), tyrosine kinase with Ig and eprdermal growth factor (EGF) homology domains 2 (TIE2)-espressing monocytes (TEMs), glypican-3 (GPC3), Golgi protein 73 (GP73), interleukin-6 (IL-6), and squamous cell carcinoma antigen (SCCA) have been proposed as biomarkers for the early detection of HCC. The diagnosis of HCC is primarily based on noninvasive standard imaging methods, such as ultrasound (US), dynamic multiphasic multidetector-row CT (MDCT) and magnetic resonance imaging (MRI). Some experts advocate gadolinium diethyl-enetriamine pentaacetic acid (Gd-EOB-DTPA) MRI and contrast-enhanced US as the promising imaging madalities of choice. With regard to recent advancements in tissue markers, many cuting-edge technologies using genome-wide DNA microarrays, qRT-PCR, and proteomic and inmunostaining studies have been implemented in an attempt to identify markers for early diagnosis of HCC. Only less than half of HCC patients at initial diagnosis are at an early stage treatable with curative options: local ablation, surgical resection, or liver transplant. Transarterial chemoembolization (TACE) is considered the standard of care with palliation for intermediate stage HCC. Recent innovative procedures using drug-eluting-beads and radioembolization using Yttrium-90 may exhibit beneficial effects in HCC treatment. During the past few years, several molecular targeted agents have been evaluated in clinical trials in advanced HCC. Sorafenib is currently the only approved systemic treatment for HCC. It has been approved for the therapy of asymptomatic HCC patients with well-preserved liver function who are not candidates for potentially curative treatments, such as surgical resection or liver transplantation. In the USA, Europe and particularly Japan, hepatitis C virus (HCV) related HCC accounts for most liver cancer, as compared with Asia-Pacific regions, where hepatitis B virus (HBV) may play a more important role in HCC development. HBV vaccination, while a vaccine is not yet available against HCV, has been recognized as a best primary prevention method for HBV-related HCC, although in patients already infected with HBV or HCV, secondary prevention with antiviral therapy is still a reasonable strategy. In addition to HBV and HCV, attention should be paid to other relevant HCC risk factors, including nonalcoholic fatty liver disease due to obesity and diabetes, heavy alcohol consumption, and prolonged aflatoxin exposure. Interestingly, coffee and vitamin K2 have been proven to provide protective effects against HCC. Regarding tertiary prevention of HCC recurrence after surgical resection, addition of antiviral treatment has proven to be a rational strategy.

Keywords

Hepatocellular carcinoma;hepatitis B virus;hepatitis C virus;transarterial chemoembolization

References

  1. Wang CH, Chang KH (2012). Long-term assessment of hepaticellular carcinoma riask in chronic hepatitis C patients with sustained viral response to antiviral treatment. Gastroenterol, 142, 1060. https://doi.org/10.1053/j.gastro.2012.03.012
  2. Wu CY, Chen YJ, Ho HJ, et al (2012). Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA, 308, 1906-4. https://doi.org/10.1001/2012.jama.11975
  3. Wong GLH, Wong VWS (2013). Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. World J Gastroenterol, 19, 6515-2. https://doi.org/10.3748/wjg.v19.i39.6515
  4. Xie H, Ma H, Zhou D (2013). Plasma HULC as a Promising Novel Biomarker for the Detection of Hepatocellular Carcinoma. Biomed Res Int, 2013, 136106.
  5. Yoshizawa H (2002). Hepatocellular carcinoma associated with hepa- titis C virus infection in Japan: projection to other countries in the foreseeable future. Oncol, 62, 8-17. https://doi.org/10.1159/000048270
  6. Yoshizawa H, Tanaka J, Miyakawa Y (2006). National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population. Intervirology, 49, 7-17. https://doi.org/10.1159/000087257
  7. Yuen MF, Tanaka Y, Fong DY, et al (2009). Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol, 50, 80-8. https://doi.org/10.1016/j.jhep.2008.07.023
  8. Yang HI, Yuen MF, Chan HL, et al (2011). Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol, 12, 568-4. https://doi.org/10.1016/S1470-2045(11)70077-8
  9. Yu NC, Chaudhari V, Raman SS, et al (2011). CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol, 9, 161-7. https://doi.org/10.1016/j.cgh.2010.09.017
  10. Zhu AX, finn RS, Mulcahy M, et al (2013). A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res, 19, 6614-3. https://doi.org/10.1158/1078-0432.CCR-13-1442
  11. Zoutendijk R, Reijnders JG, Zoulim F, et al (2013). Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut, 62, 760-5. https://doi.org/10.1136/gutjnl-2012-302024
  12. Zhu AX, Kudo M, Assenat E, et al (2014). EVOLVE-1 Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib. J Clin Oncol, in press.
  13. Sakai I, Hashimoto S, Yoda M, et al (1994). Novel role of vitamin K2: a potent inducer of differentiation of various human myeloid leukemia cell lines. Biochem Biophys Res Commun, 205, 1305-10. https://doi.org/10.1006/bbrc.1994.2807
  14. Shiina S, Teratani T, Obi S, et al (2005). A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterol, 129, 122-30. https://doi.org/10.1053/j.gastro.2005.04.009
  15. Sterling RK, Jeffers L, Gordon F, et al (2007). Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol, 102, 2196-5. https://doi.org/10.1111/j.1572-0241.2007.01405.x
  16. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, et al (2009). Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther, 30, 37-47. https://doi.org/10.1111/j.1365-2036.2009.04014.x
  17. Salem R, Lewandowski RJ, Mulcahy MF, et al (2010). Radioembolization for hepatocellular carcinoma using Yttrium-90 micro- spheres: a comprehensive report of longterm outcomes. Gastroenterology, 138, 52-64. https://doi.org/10.1053/j.gastro.2009.09.006
  18. Sano K, Ichikawa T, Motosugi U, et al (2011). Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology, 261, 834-4. https://doi.org/10.1148/radiol.11101840
  19. Tsai SL, Huang GT, Yang PM, et al (1990). Plasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinoma. Hepatol, 11, 481-8. https://doi.org/10.1002/hep.1840110321
  20. Trevisani F, D'Intino PE, Morselli-Labate AM, et al (2001). Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol, 34, 570-5. https://doi.org/10.1016/S0168-8278(00)00053-2
  21. Tateishi R, Yoshida H, Matsuyama Y, et al (2008). Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int, 2, 17-30. https://doi.org/10.1007/s12072-007-9038-x
  22. Triolo M, Corte CD, Colombo M (2014). Impact of HBV therapy on the incidence of hepatocellular carcinoma. Liver Int, 34, 139-5. https://doi.org/10.1111/liv.12394
  23. Villanueva A, Minguez B, Forner A, et al (2010). Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med, 61, 317-28. https://doi.org/10.1146/annurev.med.080608.100623
  24. Wogan GN (1992). Aflatoxins as risk factors for hepatocellular carcinoma in humans. Cancer Res, 52, 2114-8.
  25. Wang RT, Koretz RL, Yee HF Jr (2003). Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am J Med, 115, 554-9. https://doi.org/10.1016/S0002-9343(03)00449-2
  26. Wilhelm SM, Carter C, Tang L, et al (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 64, 7099-109. https://doi.org/10.1158/0008-5472.CAN-04-1443
  27. Wurmbach E, Chen YB, Khitrov G, et al (2007). Genomewide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatol, 45, 938-7. https://doi.org/10.1002/hep.21622
  28. Wong VW, Chan SL, Mo F, et al (2010). Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol, 28, 1660-5. https://doi.org/10.1200/JCO.2009.26.2675
  29. Brechot C, Gozuacik D, Murakami Y, Paterlini-Brechot P (2000). Molecular basis for the development of the hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol, 10, 211-31. https://doi.org/10.1006/scbi.2000.0321
  30. Burrel M, Llovet JM, Ayuso C, et al (2003). MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatol, 38, 1034-2. https://doi.org/10.1002/hep.1840380430
  31. Bravi F, Bosetti C, Tavani A, et al (2007). Coffee drinking and hepatocellular carcinoma risk: a meta- analysis. Hepatol, 46, 430-5. https://doi.org/10.1002/hep.21708
  32. Bruix J, Sherman M (2011). American association for the study of liver diseases management of hepatocellular carcinoma: an update. Hepatol, 53, 1020-2. https://doi.org/10.1002/hep.24199
  33. Bruix J, Tak WY, Gasbarrini A, et al (2013). Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer, 49, 3412-9. https://doi.org/10.1016/j.ejca.2013.05.028
  34. Chen HL, Chang MH, Ni YH, et al (1996). Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA, 276, 906-8. https://doi.org/10.1001/jama.1996.03540110060032
  35. Chang MH, Chen CJ, Lai MS, et al (1997). For the Taiwan childhood hepatoma study group. universal hepatitis b vaccination in taiwan and the incidence of hepatocellular carcinoma in Children. N Engl J Med, 336, 1855-9. https://doi.org/10.1056/NEJM199706263362602
  36. Caldwell SH, Oelsner DH, Iezzoni JC, et al (1999). Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatol, 29, 664-9. https://doi.org/10.1002/hep.510290347
  37. Andea L, Isgro G, Pleguezueli M et al (2009). Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis. World J Hepatol, 1, 48-61. https://doi.org/10.4254/wjh.v1.i1.48
  38. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA (1994). Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology, 107, 1103-9.
  39. Chang MH, Shau WY, Chen CJ, et al (2000). Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA, 284, 3040-2. https://doi.org/10.1001/jama.284.23.3040
  40. Capurro M, Wanless IR, Sherman M, et al (2003). Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterol, 125, 89-7. https://doi.org/10.1016/S0016-5085(03)00689-9
  41. Capurro M, Wanless IR, Sherman M, et al (2003). Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterol, 125, 89-97. https://doi.org/10.1016/S0016-5085(03)00689-9
  42. Chang MH, Chen TH, Hsu HM, (2005). Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res, 11, 7953-7 https://doi.org/10.1158/1078-0432.CCR-05-1095
  43. Cuadrado A, Orive A, Garcia-Suarez C, et al (2005). Nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma. Obes Surg, 15, 442-6. https://doi.org/10.1381/0960892053576596
  44. Chen CL, Yang HI, Yang WS, et al (2008). Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterol, 135, 111-21. https://doi.org/10.1053/j.gastro.2008.03.073
  45. Cheng AL, Kang YK, Chen Z, et al (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol, 10, 25-34. https://doi.org/10.1016/S1470-2045(08)70285-7
  46. Chang MH, You SL, Chen CJ, et al (2009). Decreased incidence of hepatocellular carcinoma in hepatitis B vaccines: a 20-year follow-up study. J Natl Cancer Inst, 101, 1348-5. https://doi.org/10.1093/jnci/djp288
  47. Cohn A, Kelley RK, Yang TS, et al (2012). Activity of cabozantinib (XL184) in hepatocellular carcinoma patients: results from a phase II randomized discontinuation trial (RDT), J Clin Oncol, 30, 4007.
  48. Donato F, Tagger A, Gelatti U, et al (2002). Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol, 155, 323-1. https://doi.org/10.1093/aje/155.4.323
  49. Di Bisceglie AM, Sterling, RK, Chung RT, et al (2005). Serum ${\alpha}$-fetoprotein levels in patients with advanced hepatitis : results from the HALT-C Trial. J Hepatol, 43, 434-1. https://doi.org/10.1016/j.jhep.2005.03.019
  50. Di Tommaso L, Franchi G, Park YN, et al (2007). Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatol, 45, 725-4. https://doi.org/10.1002/hep.21531
  51. Dohmen K, Kawano A, Takahashi K, et al (2013). The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C. Hepatogastroenterol, 60, 2034-8.
  52. Dhayat SA, Mardin WA, Kohler G, et al (2014). The microRNA-200 family-A potential diagnostic marker in hepatocellular carcinoma? J Surg Oncol, in press.
  53. El-Serag HB (2012). Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology,142, 1264-3. https://doi.org/10.1053/j.gastro.2011.12.061
  54. Franca AVC, junior, LE, Lima BLG, Martinelli ALC, Carrilho, FL (2004). Diagnosis, staging and treatment of hepatoceelualr carcinoma. Brazilian Journal of Medical and Biological Research, 37, 1689-705.
  55. Franceschi S, Montella M, Polesel J, et al (2006). Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. Cancer Epidemiol Biomarkers Prev, 15, 683-9. https://doi.org/10.1158/1055-9965.EPI-05-0702
  56. Forner A, Vilana R, Ayuso C, et al (2008). Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology, 47, 97-4.
  57. Giannelli G, Marinosci F, Trerotoli P, et al (2005). SCCA antigen combined with ${\alpha}$-fetoprotein as serologic markers of HCC. Int J Cancer, 117, 506-9. https://doi.org/10.1002/ijc.21189
  58. Hsu HM, Chen DS, Chuang CH, et al (1988). Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen-carrier mothers. JAMA, 260, 2231-5. https://doi.org/10.1001/jama.1988.03410150079034
  59. Habu D, Shiomi S, Tamori A, et al (2004). Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA, 292, 358-1. https://doi.org/10.1001/jama.292.3.358
  60. Hsia CY, Huo TI, Chiang SY, et al (2007). Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Eur J Surg Oncol, 33, 208-2. https://doi.org/10.1016/j.ejso.2006.10.036
  61. Hilgard P, Hamami M, Fouly AE, et al (2010). Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatol, 52, 1741-9. https://doi.org/10.1002/hep.23944
  62. Hsu YC, Ho HJ, Wu MS, Lin JT, Wu CY (2013). Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatol, 58, 150-7. https://doi.org/10.1002/hep.26300
  63. Hosaka T, Suzuki F, Kobayashi M, et al (2013). Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatol, 58, 98-7.
  64. International Consensus Group for Hepatocellular Neoplasia (2009). Pathological diagnosis of early hepatocellular carcinoma: a report of the international concensus group for hepatocellular neoplasia. Hepatol, 49, 658-4. https://doi.org/10.1002/hep.22709
  65. Ichikawa T, Sano K, Morisaka H (2014). Diagnosis of Pathologically Early HCC with EOB-MRI: Experiences and Current Consensus. Liver Cancer, 3, 97-107. https://doi.org/10.1159/000343865
  66. Joo I, Choi BI. (2012). New paradigm for management of hepatocellular carcinoma by imaging. Liver Cancer, 1, 94-9. https://doi.org/10.1159/000342404
  67. Koike Y, Shiratori Y, Sato S, et al (2001). Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer, 91, 561-9. https://doi.org/10.1002/1097-0142(20010201)91:3<561::AID-CNCR1035>3.0.CO;2-N
  68. Kudo M, Imanaka K, Chida N, et al (2011). Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer, 47, 2117-27. https://doi.org/10.1016/j.ejca.2011.05.007
  69. Kudo M, Han G, finn RS, et al (2014). Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase 3 trial. Hepatol, 60, 1697-7. https://doi.org/10.1002/hep.27290
  70. Llovet JM, Bru C, Bruix J (1999). Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis, 19, 329-8. https://doi.org/10.1055/s-2007-1007122
  71. Llovet JM, Fuster J, Bruix J (1999). Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatol, 30, 1434-40. https://doi.org/10.1002/hep.510300629
  72. Lim SG, Mohammed R, Yuen MF, Kao JH (2009). Prevention of hepatocellular carcinoma in hepatitis B virus infection. J Gastroenterol Hepatol, 24, 1352-7. https://doi.org/10.1111/j.1440-1746.2009.05985.x
  73. Llovet JM, Bruix J (2003). Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatol, 37, 429-42. https://doi.org/10.1053/jhep.2003.50047
  74. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X (2004). Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol, 10, 2878-2. https://doi.org/10.3748/wjg.v10.i19.2878
  75. Llovet JM, Chen Y, Wurmbach E, et al (2006). A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterol, 31, 1758-7.
  76. Larsson SC, Wolk A (2007). Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology, 132, 1740-5. https://doi.org/10.1053/j.gastro.2007.03.044
  77. Llovet JM, Ricci S, Mazzaferro V, et al (2008). SHARP Investigators Study Group Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359, 378-90. https://doi.org/10.1056/NEJMoa0708857
  78. Lok AS, Sterling RK, Everhart JE, et al (2010). Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterol, 138, 493-2. https://doi.org/10.1053/j.gastro.2009.10.031
  79. Lencioni R, Zou J, Leberre M, et al (2010). Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (SPACE). J Clin Oncol, 28, 15. https://doi.org/10.1200/JCO.2008.20.9288
  80. Lok AS, Everhart JE, Wright EC, et al (2011). Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterol, 140, 840-9. https://doi.org/10.1053/j.gastro.2010.11.050
  81. Lok AS, Gardiner DF, Lawitz E. et al (2012). Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med, 366, 216-4. https://doi.org/10.1056/NEJMoa1104430
  82. Lee JM, Yoon JH, Joo I, Woo HS (2012). Recent advances in CT and MR imaging for evaluation of hepatocellular carcinoma. Liver Cancer, 1, 22-40. https://doi.org/10.1159/000339018
  83. Lin IY, Yen CH, Liao YJ, et al (2013). Identification of FKBP11 as a biomarker for hepatocellular carcinoma. Anticancer Res, 33, 2763-9.
  84. Llovet JM, Decaens T, Raoul JL, et al (2013). Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol, 31, 3509-6. https://doi.org/10.1200/JCO.2012.47.3009
  85. Mazzaferro V, Regalia E, Doci R, et al (1996). Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med, 334, 693-9. https://doi.org/10.1056/NEJM199603143341104
  86. Matteoni CA, Younossi ZM, Gramlich T, et al (1999). Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterol, 116, 1413-9. https://doi.org/10.1016/S0016-5085(99)70506-8
  87. Marrero JA, Su GL, Wei W, et al (2003). Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatol, 37, 1114-1. https://doi.org/10.1053/jhep.2003.50195
  88. Marrero JA, Romano PR, Nikolaeva O, et al (2005). GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol, 43, 1007-2. https://doi.org/10.1016/j.jhep.2005.05.028
  89. Mazzaferro V, Romito R, Schiavo M, et al (2006). HCC Italian task force. prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatol, 44, 1543-54. https://doi.org/10.1002/hep.21415
  90. Masuzaki R, Yoshida H, Omata M (2010). Does chemotherapy prevent HCV-related hepatocellular carcinoma? Pros Dig Liver Dis, 42, 281-6. https://doi.org/10.1016/S1590-8658(10)60517-8
  91. Malagari K, Pomoni M, Kelekis A, et al (2010). Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol, 33, 541-51. https://doi.org/10.1007/s00270-009-9750-0
  92. Morgan RL, Baack B, Smith BD, et al (2013). Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med, 158, 329-7. https://doi.org/10.7326/0003-4819-158-5-201303050-00005
  93. Matsubara T, Kanto T, Kuroda S, et al (2013). TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. Hepatol, 57, 1416-5. https://doi.org/10.1002/hep.25965
  94. Michelotti GA, Machado MV, Diehl AM (2013). NAflD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol, 10, 656-5. https://doi.org/10.1038/nrgastro.2013.183
  95. Murakami T, Tsurusaki M (2014). Hypervascular benign and malignant liver tumors that require differentiation from hepatocellular carcinoma: key points of imaging diagnosis. Liver Cancer, 3, 85-96. https://doi.org/10.1159/000343864
  96. Ng KK, Vauthey JN, Pawlik TM, et al (2005). Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol, 12, 364-3. https://doi.org/10.1245/ASO.2005.06.004
  97. NCCN Clinical Practical Guidances in Hepatobiliary Cancers, 2013. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp Accessed
  98. Nakazawa T, Hidaka H, Shibuya A, et al (2014). Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. BMC Gastroenterol, 14, 84-90. https://doi.org/10.1186/1471-230X-14-84
  99. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
  100. Pawlik TM, Poon RT, Abdalla EK, et al (2005). Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery, 137, 403-10. https://doi.org/10.1016/j.surg.2004.12.012
  101. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A (2010). Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos (t)ide therapy: a systematic review. J Hepatol, 53, 348-6. https://doi.org/10.1016/j.jhep.2010.02.035
  102. Park MJ, Kim YK, Lee MW, et al (2012). Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns. Radiol, 264, 761-70. https://doi.org/10.1148/radiol.12112517
  103. Park JW, Koh YH, Kim HB, et al (2012). Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol, 56, 1336-2. https://doi.org/10.1016/j.jhep.2012.01.006
  104. Qi J, Wang J, Katayama H, Sen S, Liu SM (2013). Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma, 60, 135-2.
  105. Roskams T, Kojiro M (2010). Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis, 30, 17-25. https://doi.org/10.1055/s-0030-1247129

Cited by

  1. 3D CACT-assisted Radiofrequency Ablation Following Transarterial Chemoembolization for Hepatocellular Carcinoma: Early Experience vol.16, pp.17, 2015, https://doi.org/10.7314/APJCP.2015.16.17.7897
  2. Effects of Epothilone A in Combination with the Antidiabetic Drugs Metformin and Sitagliptin in HepG2 Human Hepatocellular Cancer Cells: Role of Transcriptional Factors NF-κB and p53 vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.993
  3. Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives vol.12, pp.2, 2017, https://doi.org/10.1371/journal.pone.0171840
  4. Comparative effectiveness of first-line radiofrequency ablation versus surgical resection and transplantation for patients with early hepatocellular carcinoma vol.123, pp.10, 2017, https://doi.org/10.1002/cncr.30531
  5. miR-155-5p modulates malignant behaviors of hepatocellular carcinoma by directly targeting CTHRC1 and indirectly regulating GSK-3β-involved Wnt/β-catenin signaling vol.17, pp.1, 2017, https://doi.org/10.1186/s12935-017-0469-8
  6. Genetic biomarkers for hepatocellular cancer risk in a caucasian population vol.23, pp.36, 2017, https://doi.org/10.3748/wjg.v23.i36.6674
  7. Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma vol.42, pp.3, 2017, https://doi.org/10.1007/s12038-017-9695-4
  8. Expression of OTUB1 in hepatocellular carcinoma and its effects on HCC cell migration and invasion vol.49, pp.8, 2017, https://doi.org/10.1093/abbs/gmx056
  9. Antibody to human α-fetoprotein inhibits cell growth of human hepatocellular carcinoma cells by resuscitating the PTEN molecule: in vitro experiments vol.50, pp.6, 2017, https://doi.org/10.3892/ijo.2017.3982
  10. Diagnostic value of serum squamous cell carcinoma antigen for hepatocellular carcinoma: a systematic review and meta-analysis vol.77, pp.1, 2017, https://doi.org/10.1080/00365513.2016.1238504
  11. Long Non-Coding RNA SNHG6 as a Potential Biomarker for Hepatocellular Carcinoma pp.1532-2807, 2017, https://doi.org/10.1007/s12253-017-0241-3
  12. A double suicide gene system driven by vascular endothelial growth factor promoter selectively kills human hepatocellular carcinoma cells vol.11, pp.5, 2016, https://doi.org/10.3892/ol.2016.4360
  13. Specific expression of proton-coupled oligopeptide transporter 1 in primary hepatocarcinoma-a novel strategy for tumor-targeted therapy vol.14, pp.4, 2017, https://doi.org/10.3892/ol.2017.6724
  14. Bioinformatics identification of crucial genes and pathways associated with hepatocellular carcinoma vol.38, pp.6, 2018, https://doi.org/10.1042/BSR20181441
  15. Increased EXT1 gene copy number correlates with increased mRNA level predicts short disease-free survival in hepatocellular carcinoma without vascular invasion vol.97, pp.39, 2018, https://doi.org/10.1097/MD.0000000000012625